FDA advisers to discuss easing peptide restrictions amid safety concerns
10 reported
Advisers to the Food and Drug Administration will hold a meeting about whether to ease restrictions on access to some research peptides, a group of drugs with a zealous following and thin evidence to support them, according to a report from The Guardian. If restrictions are eased, US compounding pharmacies would be able to produce and fill prescriptions for Americans, effectively legalizing a thriving gray market. The FDA’s pharmacy compounding advisory committee is scheduled to meet on 23-24 July and discuss seven peptides: BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax and Epitalon. The FDA is not bound to follow the committee’s advice, but it usually does. The push for change comes after a 2023 decision by the Biden administration to ban compounding pharmacies from producing 19 research peptides due to safety concerns. The US health secretary, Robert F Kennedy Jr, recently characterized the Biden administration’s actions as “illegal” on The Joe Rogan Experience. Critics worry the regulatory change is a fait accompli, no matter the lack of evidence, and point to Kennedy’s efforts to reduce the number of vaccines children receive as precedent.
What’s reported
The FDA’s pharmacy compounding advisory committee is scheduled to meet on 23-24 July to discuss seven peptides: BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax and Epitalon.
If restrictions are eased, US compounding pharmacies would be able to produce and fill prescriptions for Americans.
The push for change follows a 2023 Biden administration ban on compounding pharmacies producing 19 research peptides due to safety concerns.
The FDA cited risks including priapism and aiding tumor growth as reasons for the ban.
US health secretary Robert F Kennedy Jr characterized the Biden administration’s actions as “illegal” on The Joe Rogan Experience.
Evidence of safety and efficacy in humans for these peptides ranges from thin to nonexistent, according to the article.
At least one poll suggests 90% of physicians are worried about patients’ self-directed peptide use.
Wall Street analysts estimate telehealth peptide prescribing could reach $2.2bn per year, with Hims & Hers alone capturing as much as $440m if restrictions are eased.
Kennedy said he is a “big fan” of peptides and has used them himself.
Kennedy fired all 17 members of a federal vaccine advisory committee and replaced them with ideological allies in June 2025; a court blocked the panel’s changes and the subject is still being litigated.
Key figures
Mohammed Chammout, retail pharmacist in Michigan
Dr Eric Topol, director and founder of the Scripps Research Translational Institute and author of Super Agers: An Evidence-Based Approach to Longevity
Dr Flynn McGuire, researcher who studied BPC-157
Dr Anant Vinjamoori, chief medical officer of Hims
Robert F Kennedy Jr, US health secretary
Sources: The Guardian
